Please use this identifier to cite or link to this item:
Title: Drug reprofiling history and potential therapies against Parkinson’s disease
Authors: Latif, Komal
Ullah, Aman
Shkodina, Anastasiia D.
Boiko, Dmytro I.
Rafique, Zakia
Alghamdi, Badrah S.
Alfaleh, Mohamed A.
Ashraf, Ghulam Md.
Шкодіна, Анастасія Дмитрівна
Бойко, Дмитро Іванович
Issue Date: 26-Oct-2022
Citation: Drug reprofiling history and potential therapies against Parkinson’s disease / K. Latif, A. Ullah, A. D. Shkodina [et al.] // Frontiers in Pharmacology. – 2022. – № 13. – E 1028356.
Abstract: Given the high whittling down rates, high costs, and moderate pace of new medication, revelation, and improvement, repurposing “old” drugs to treat typical and uncommon illnesses is progressively becoming an appealing proposition. Drug repurposing is the way toward utilizing existing medications in treating diseases other than the purposes they were initially designed for. Faced with scientific and economic challenges, the prospect of discovering new medication indications is enticing to the pharmaceutical sector. Medication repurposing can be used at various stages of drug development, although it has shown to be most promising when the drug has previously been tested for safety. We describe strategies of drug repurposing for Parkinson’s disease, which is a neurodegenerative condition that primarily affects dopaminergic neurons in the substantia nigra. We also discuss the obstacles faced by the repurposing community and suggest new approaches to solve these challenges so that medicine repurposing can reach its full potential.
Keywords: central nervous system
drug discovery
drug repurposing
Parkinson’s disease
DOI: 10.3389/fphar.2022.1028356
Appears in Collections:Наукові праці. Кафедра нервових хвороб
Наукові праці. Кафедра психіатрії, наркології та медичної психології

Files in This Item:
File Description SizeFormat 
Drug_reprofiling_history_and_potential_therapies_against_Parkinsons_disease.pdf1,28 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.